First Treatment Approved for Molluscum Contagiosum
Topical cantharidin (Ycanth) was approved as the first treatment specifically…
Browsing Tag
molluscum
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica…
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of the transaction, which is expected to occur by the end of…
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical…
– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination…
FDA Warns Against Using Bogus Treatments for Molluscum
Physician’s Briefing Staff
MONDAY, June 5, 2023 (HealthDay News) -- Patients may be tempted to treat little skin bumps on their own, but that…
At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks
NEW ORLEANS -- Almost 40% of patients with molluscum contagiosum, some with dozens of lesions, had complete or near-complete…
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for…
<!-- Name:DistributionId Value:8777554 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206)…
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin…
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster…
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been…
Novel Nitric Oxide Gel Clears Kids’ Molluscum Contagiosum Lesions
A novel nitric oxide-releasing gel led to significantly more patients achieving complete…
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology…
DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical…